Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder

REFERENCES

• Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075–107.
   PubMed Web of Science ®Google Scholar
• Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996; 155: 105–9.
   PubMedGoogle Scholar
• Murphy WM, Emerson LD, Chandler RW, Moinuddin SM, Soloway MS. Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. J Urol 1986; 136: 815–19.
   Google Scholar
• Raab SS, Slagel DD, Jensen CS, Teague MW, Save11 VH, Ozkutlu D, Lenel JC, Cohen MB. Low-grade transitional cell carcinoma of the urinary bladder: application of select cytologic criteria to improve diagnostic accuracy. Mod Pathol 1996; 9: 225–32.
   Google Scholar
• Devonec M, Darzynkiewicz Z, Kostyrka-Claps ML, Collste L, Whitmore WF Jr, Melamed MR. Flow cytometry of low stage bladder tumors: correlation with cytologic and cystoscopic diag-nosis. Cancer 1982; 49: 109–18.
   Google Scholar
• Dean PJ, Murphy WM. Importance of urinary cytology and future role of flow cytometry. Urology 1985; 26 Suppl: 11–15.
   Google Scholar
• Abel PD. Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol 1988; 62: 103–9.
   PubMedGoogle Scholar
• Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, Hawkins IR. Super- ficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083–6.
   Google Scholar
• Achtstatter T, Moll R, Moore B, Franke WW. Cytokeratin polypeptide patterns of different epithelia of the human male urogenital tract: immunofluorescence and gel electrophoretic stu-dies. J Histochem Cytochem 1985; 33: 415–26.
   PubMed Web of Science ®Google Scholar
• Carbin BE, Collins VP, Ekman P. Tissue poly-peptide antigen (TPA), some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium. Urol Res 1987; 15: 191–4.
   Google Scholar
• Devonec M, Hijazi A, Bringuier PP, Dutrieux-Berger N, Perrin P, Revillard JP. Flow cytometric demonstration of shared antigens between human bladder cancer cells and normal host macro-phages. Eur Urol 1989; 16: 57–62.
   Google Scholar
• Feitz WF, Beck HL, Smeets AW, Debruyne FM, Vooijs GP, Herman CJ, Ramaekers FC. Tissue-specific markers in flow cytometry of urological cancers: cytokeratins in bladder carcinoma. Int J Cancer 1985; 36: 349–56.
   Google Scholar
• Schaafsma HE, Ramaekers FC, van Muijen GN, Lane EB, Leigh IM, Robben H, Huijsmans A, Ooms EC, Ruiter DJ. Distribution of cytokeratin polypeptides in human transitional cell carcino-mas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol 1990; 136: 329–43.
   Google Scholar
• Schaafsma HE, Ramaekers FC, van Muijen GN, Robben H, Lane EB, Leigh IM, Ooms EC, Schalken JA, van Moorselaar RJ, Ruiter DJ. Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases. Am J Pathol 1991; 139: 1389–400.
   Google Scholar
• Chen YJ, Huang CN, Wu WJ, Chiang PH, Huang CH, Chang SF. The altered expression of cytokeratin polypeptides in carcinomas of human bladder. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1994; 10: 9–15.
   PubMedGoogle Scholar
• Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th ed. New York: John Wiley Inc, 1997.
   Google Scholar
• D'Hallewin MA, Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996; 155: 475–6.
   PubMed Web of Science ®Google Scholar
• Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996; 156: 1280–5.
   Google Scholar
• Heicappell R, Wettig IC, Schostak M, Muller M, Steiner U, Sauter T, Miller K. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999; 35: 81–7.
   Google Scholar
• Moll R, Achtstatter T, Becht E, Balcarova-Stander J, Ittensohn M, Franke WW. Cytoker-atins in normal and malignant transitional epithe- hum. Maintenance of expression of urothelial differentiation features in transitional cell carci-nomas and bladder carcinoma cell culture lines. Am J Pathol 1988; 132: 123–44.
   Google Scholar
• Hamden P, Southgate J. Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol 1997; 50: 1032–3.
   PubMed Web of Science ®Google Scholar
• Guelstein VI, Tchipysheva TA, Ermilova VD, Troyanovsky SM. Immunohistochemical localiza-tion of cytokeratin 17 in transitional cell carcino-mas of the human urinary tract. Virchows Arch B Cell Pathol Incl Mol Pathol 1993; 64: 1–5.
   PubMedGoogle Scholar
• Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkom I. Expression of cytokeratin 20 in urinary cytology of patients with bladder carci-noma. Cancer 1998; 82: 349–54.
   Google Scholar
• Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkom I. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma? J Urol 1998; 160 (6 Pt 1): 1971 –4.
   Google Scholar
• Essa MH, Mangoud AM, Aly MA, el Adl M, Morsy TA. Schistosomiasis associated bladder carcinoma expression of cytokeratin. J Egypt Soc Parasitol 1990; 20: 161–7.
   PubMedGoogle Scholar
• Flam TA, Chopin DK, Leleu C, Abbou CC, Steg A, Desligneres S, Boccon-Gibod L. Immunohis-tochemical markers defined by monoclonal anti-bodies and response to bacillus Calmette-Guerin endovesical immunotherapy for superficial bladder tumors. Eur Urol 1990; 17: 338–42.
   Google Scholar
• Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, Le Guillou M. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carci-noma. J Urol 1997; 158: 338–41.
   Google Scholar
• Senga Y, Kimura G, Hattori T, Yoshida K. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer. Urology 1996; 48: 703 — 10.
   PubMed Web of Science ®Google Scholar
• Ramaekers F, Huysmans A, Moesker 0, Schaart G, Herman C, Vooijs P. Cytokeratin expression during neoplastic progression of human transi-tional cell carcinomas as detected by a monoclonal and a polyclonal antibody. Lab Invest 1985; 52: 31 — 8.
   Google Scholar
• Cintorino M, Del Vecchio MT, Bugnoli M, Petracca R, Leoncini P. Cytokeratin pattern in normal and pathological bladder urothelium: immunohistochemical investigation using mono-clonal antibodies. J Urol 1988; 139: 428–32.
   PubMed Web of Science ®Google Scholar
• Hijazi A, Devonec M, Bouvier R, Revillard JP. Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors. J Urol 1989; 141: 522–6.
   PubMed Web of Science ®Google Scholar
• Basta MT, Attallah AM, Seddek MN, el Mohamady H, Al Hilaly ES, Atwaan N, Ghoneim M. Cytokeratin shedding in urine: a biological marker for bladder cancer? Br J Urol 1988; 61: 116–21.
   Google Scholar
• Baker WC, deVere WR, Rossitto PV, MM BH, Cardiff RD. Quantitative analysis of keratin 18 in the urine of patients with bladder cancer. J Urol 1988; 140: 436–9.
   Google Scholar
• Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Initial evaluation of the new urinary bladder cancer rapid test in the detection of transitional cell carcinoma of the bladder. Urology 1999; 54: 656–61.
   Google Scholar